ArticlePloS one2025
One step synthesis of ultrafine PHF@AuNPs nanocomposite and its application in NIR triggered photodynamic therapy.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Retraction: One step synthesis of ultrafine PHF@AuNPs nanocomposite and its application in NIR triggered photodynamic therapy.PloS one · 2026Article
- Current Perspectives on Radiosensitizers in Cancer Radiotherapy.International journal of nanomedicine · 2026Review
Corrections and comments
- Retraction · 2026-08-12Concerns/Issues about Data · Concerns/Issues about Methods · Copyright Claims · Investigation by Journal/Publisher · Lack of Approval from Third Party · Removed ·
- Retracted
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodynamic therapy (PDT) is a rapid advancing treatment for cancer therapy. The main challenges in PDT include poor absorption in the "tissue optical window" and aggregation tendency of photosensitizers (PS) such as fullerene in aqueous solutions. Herein, we developed a potent nano PS: fullerene hybrid gold nanoparticles (AuNPs) composites which were ultrafine and well-dispersed with a absorption in near infrared (NIR) region. The composites could be facilely prepared by mixing the reducing and capping agent polyhydroxyl fullerene (2 mg/mL) with HAuCl4 (2.425 mM) at equal volume for 2 h. The obtained composites were negatively charged (-26.3 mv) with the particle size of 14.3 nm. A thin layer of fullerene (~1.6 nm) was coated on the AuNPs core. AuNPs in the composites acted as the light collector, absorbing the NIR light and transferring electrons or energy to the fullerene. Consequently, the composites can be efficiently internalized by tumor cells and activated to produce reactive oxygen species (ROS) intracellularly by 808 nm laser. Enhanced PDT efficacy was observed with the IC50 value (50 μg/mL) of the light-activated cytotoxicity and a negligible dark toxicity in vitro. This research provides new insights and methods for developing NIR light-triggered fullerene@AuNPs in PDT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.